Thursday, January 26, 2012

Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33

Full Year 2011 GAAP EPS Decreased 16 Percent to $4.04 Due to a One-Time Charge

2012 Total Revenue and Adjusted EPS Expected to be in the Range of $16.1-$16.5 Billion and $5.90-$6.15, Respectively

Amgen reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010.  For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010.

Read the rest of this entry

Posted in Press Releases

Thursday, January 26, 2012

Amgen to Acquire Micromet

Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies

Micromet’s Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types

All-Cash Transaction Values Micromet at $1.16 Billion

THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) and Micromet, Inc.  (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors.

Read the rest of this entry

Posted in Press Releases

Tuesday, January 24, 2012

Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results

THOUSAND OAKS, Calif., Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Standard Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Wednesday, January 04, 2012

Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference

THOUSAND OAKS, Calif., Jan. 4, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at the Westin St. Francis in San Francisco, Calif.  Robert A. Bradway, president and chief operating officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Thursday, December 29, 2011

FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting

THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

Read the rest of this entry

Posted in Press Releases